Henan Cancer Hospital: Breast Neoplasms trials

The registry lists 39 Breast Neoplasms studies with Henan Cancer Hospital as lead sponsor. 25 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 27Phase 3 4No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNCT07706933Not applicable
• Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast CancerNot yet recruitingNCT07416253Phase 2
• Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Not yet recruitingNCT07136974Phase 2
• Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT07057427Phase 3
• Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCNot yet recruitingNCT07047755Phase 2
• Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort StudyRecruitingNCT07037576
• Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat TransplantationRecruitingNCT07037537Not applicable
• QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast CancerRecruitingNCT06967103Phase 2
• The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast CancerNot yet recruitingNCT06934733Not applicable
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT06927180Phase 2
• SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast CancerNot yet recruitingNCT06819319Phase 2
• A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingNCT06788197Phase 1/2
• NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.RecruitingNCT06781281
• ARX788 in HER2-positive Metastatic Breast Cancer PatientsRecruitingNCT06663748Phase 2
• To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer PatientsRecruitingNCT06605521
• A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBCRecruitingNCT06598046Phase 2
• Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCsNot yet recruitingNCT06475443Phase 2
• Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast CancerRecruitingNCT06276868Phase 2
• Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical TrialRecruitingNCT06176534Phase 2
• Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BCRecruitingNCT05918328Phase 2
• A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast CancerRecruitingNCT05911958Phase 2
• Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain MetastasesRecruitingNCT05769010Phase 2
• Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingNCT05296577Phase 2
• Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast CancerRecruitingNCT05063136Phase 3
• A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingNCT04547907Phase 3
• Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast CancerActive, not recruitingNCT06394661Phase 2
• A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast CancerWithdrawnNCT05474690Phase 3
• A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast CancerCompletedNCT05394285Phase 2
• Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)Status unknownNCT05359120
• Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain MetastasesStatus unknownNCT05357417Phase 2
• Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)Active, not recruitingNCT05328440Phase 2
• Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerTerminatedNCT05176080Phase 1/2
• Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBCCompletedNCT04664972Phase 2
• Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast CancerStatus unknownNCT04293276Phase 2
• SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast CancerStatus unknownNCT04213898Phase 1/2
• Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer PatientsWithdrawnNCT04199520Phase 2
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.Status unknownNCT03947242Not applicable
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2
• A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerActive, not recruitingNCT03691051Phase 2